

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35283> holds various files of this Leiden University dissertation

Author: Charehbili, Ayoub

Title: Optimising preoperative systemic therapy for breast cancer

Issue Date: 2015-09-16

Optimising preoperative systemic therapy for breast cancer

Ayoub Charehbili

Lay-out: Ayoub Charehbili
Cover design: Ayoub Charehbili
Printed by: Gildeprint Drukkerijen, The Netherlands

Optimising preoperative systemic therapy for breast cancer
Thesis, Leiden University Medical Center, the Netherlands 2015.

© Ayoub Charehbili, the Netherlands 2015.
ISBN: 978-94-6233-019-1

The printing of this thesis was made possible by the departments of Medical Oncology and Surgery of the Leiden University Medical Center, Boehringer Ingelheim, Chipsoft, Philips, Novartis, Pfizer and Galephar.

Optimising preoperative systemic therapy for breast cancer

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. Mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op 16 september 2015
klokke 16:15

door

Ayoub Charehbili

Rotterdam, 1990.

Promotiecommissie

Promotores: Prof. dr. C.J.H. van de Velde
Prof. dr. J.W.R. Nortier

Copromotor: dr. J.R. Kroep

Overige leden: dr. G.J. Liefers
prof.dr. S.C. Linn, Netherlands Cancer Institute
prof. dr. H. Putter
prof dr. V.T.H.B.M. Smit
dr. N.A.T. Hamdy

Contents

Introduction

Chapter 1	General introduction and outline of this thesis	8
-----------	---	---

Part I

Chapter 2	Can zoledronic acid be beneficial for promoting tumor response in breast cancer patients treated with neoadjuvant chemotherapy?	18
-----------	---	----

Chapter 3	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial	32
-----------	---	----

Chapter 4	Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: a meta-analysis of randomized trials	46
-----------	--	----

Chapter 5	Accuracy of MRI for treatment response assessment after taxane- and anthracyclin- based neoadjuvant chemotherapy in HER2-negative breast cancer	58
-----------	---	----

Chapter 6	Vitamin D (25-OH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer	70
-----------	---	----

Part II

Chapter 7	Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review	82
-----------	---	----

Chapter 8	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer patients	98
-----------	--	----

Chapter 9	Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients	116
-----------	---	-----

Summary & Discussion

Chapter 10	Summary, general discussion and future perspectives	126
------------	---	-----

